1. Introduction {#sec1}
===============

Optic disc drusen (ODD) are calcified hyaline-like deposits in the optic nerve head that are mainly located in front of the lamina cribrosa. They are often bilateral (67%-91%), and their incidence is 0.4%-20.4% in general population while there is female preponderance in their prevalence. They are usually benign and vision sparing; however, they may rarely complicate with visual field defects, haemorrhages, choroidal neovascularization (CNV), serous maculopathy, vascular occlusion, and nonarteritic ischemic optic neuropathy (NAION) \[[@B1]\].

Various imaging methods have been used in order to detect ODD accurately and reliably, which include ultrasonography (USG), enhanced depth imaging-OCT (EDI-OCT), fluorescein fundus angiography (FFA), and fundus autofluorescence (FAF), and the newest application is optical coherence tomography angiography (OCTA, Optovue, Inc., Fremont, CA, USA) \[[@B2]\].

Noninvasive imaging of the retina, choroidal, and disc microvasculature is now possible with OCTA and without the use of exogenous intravenous dye injection. It can provide information for the evaluation of both structure and blood flow. It particularly allows the assessment of CNV morphology and features activity as well as the timing of and response to anti-VEGF treatment of CNV \[[@B3], [@B4]\]. It has been increasingly used for the diagnosis and imaging of paediatric retinal vascular disease and especially CNV as it is both reliable and noninvasive \[[@B5]\].

The OCTA studies in the literature mainly focus on microvascular changes associated with optic disc drusen. To the best of our knowledge, only Ong et al. demonstrated inactivate CNV associated with ODD in 1 case with OCTA in a series of 8 paediatric patients with CNV. However, this is the first time to report an interesting change in CNV after injection and long-term follow-up findings.

2. Case Report {#sec2}
==============

A 14-year-old girl was referred to us with complaints of visual loss and metamorphopsia in both eyes that had persisted for 1 week. Her best-corrected visual acuity (BCVA) was 20/32 in the right eye and 20/25 in the left eye. Her ocular and systemic history was unremarkable. Her intraocular pressure and anterior segment examination were normal. Dilated fundus examination revealed elevated optic discs with blurred margins in both eyes. In addition, slightly elevated yellow lesion extending from optic nerve head to the macula was observed bilaterally (Figures [1(a)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"}). The patient underwent imaging with colour fundus photography, FAF, FFA, spectral-domain optic coherence tomography (SD-OCT, Cirrus HD OCT 5000, Carl Zeiss Meditec Inc., Dublin, CA, USA), OCTA, orbital USG, and computed tomography (CT). FAF showed bilateral aspect of white refractile and hyperautofluorescence bodies on the surface of the optic nerve linked with the drusen and a hypoautofluorescent and hyperautofluorescent lesion in the papillomacular region (Figures [1(b)](#fig1){ref-type="fig"} and [1(e)](#fig1){ref-type="fig"}). FFA showed no hyperfluorescence or leakage with blurred borders of the optic disc, and early hyperfluorescence and intense leakage that might be associated with CNV were observed in both eyes with the right eye predominance (Figures [1(c)](#fig1){ref-type="fig"} and [1(f)](#fig1){ref-type="fig"}). The peripheral retina was normal. B-mode USG showed hyperechogenic appearance, and orbital CT revealed papilla as bright spots which might be associated with optic disc drusen ([Figure 1(g)](#fig1){ref-type="fig"}). SD-OCT showed retinal thickening, subretinal hyperreflectivity in the papillomacular region bilaterally, and subfoveal fluid in the right eye (Figures [1(h)](#fig1){ref-type="fig"} and [1(i)](#fig1){ref-type="fig"}). Furthermore, macular and retinal nerve fiber layer (RNFL) thickness measurements were recorded ([Table 1](#tab1){ref-type="table"}).

OCTA revealed superficial and deep capillary density, foveal avascular zone, flow, and en face images in the macula ([Table 2](#tab2){ref-type="table"}). A large circular CNV complex with main trunk, multiple dense thin capillaries branching from the main trunk in a tree-like manner, and frequent anastomoses was observed in the papillomacular region of the right eye in the outer retina and choriocapillaris cross-sections (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}). In the left eye, CNV with main trunk, minimal vessel loops, and capillaries was observed, which was considered as slightly activated (Figures [2(c)](#fig2){ref-type="fig"} and [2(d)](#fig2){ref-type="fig"}). Moreover, radial papillary capillary density was measured with OCTA ([Table 2](#tab2){ref-type="table"}). Density was lower in the areas associated with nasal quadrant compared to the other quadrants.

All evaluations suggested CNV secondary to ODD, and intravitreal aflibercept was injected in 3 doses to the right eye and a single dose to the left eye. Three doses were injected to the right eye every other month. After the first injection, BCVA remained as 20/32 and increased to 20/25 after the second one. After the third dose of injection to the right eye and the first one to the left eye, BCVA was 20/20 in both eyes. After the injections in both eyes, SD-OCT revealed RPE irregularity in the temporal region of the optic disc and complete regression of the subretinal fluid. OCTA interestingly showed that the entire CNV compete including the main trunk disappeared (Figures [3(a)](#fig3){ref-type="fig"}[to 3(d)](#fig3){ref-type="fig"}). CNV complex was not observed with OCTA, and no significant change was observed in the peripapillary and macular vascular density measurements, and findings which might be correlated with RNFL measurements were not detected in 1-year follow-up. BCVA was preserved, and no additional injections were needed.

3. Discussion {#sec3}
=============

CNV associated with ODD is a very rare complication, which has been reported in both adults and children \[[@B6]\]. In most of the patients, CNV membranes associated with ODD occur nasally; however, they may also occur temporally resulting in serous haemorrhagic maculopathy, cystoid macular edema, and macular scarring \[[@B7]\]. Its pathogenesis is unknown. Possible mechanisms involved in this complication include the compressive effect of drusen on the surrounding blood vessels, which leads to mechanical impairment of peripapillary vascular integrity, vascular congestion, or ischemia. Retinal ischemia and the release of VEGF may be the factors that trigger the development of CNV \[[@B8], [@B9]\]. Treatment must be provided if vision is jeopardized. The modern antivascular endothelial growth factor (VEGF) medications, photodynamic therapy, and surgical removal have each been demonstrated to be successful \[[@B10]\]. Anti-VEGF agents have been increasingly preferred as the first-line treatment because they ensure high visual acuity and disease stabilization usually with fewer intravitreal injections especially in paediatric cases, and recurrence is almost never observed. Gan and Long reported complete resolution after 3 doses of injection in cases for whom aflibercept was injected for the first time \[[@B11]\]. Knape et al. reported rapid and atraumatic resolution with the combination of bevacizumab and focal laser photocoagulation \[[@B12]\]. Alkın et al. emphasized that CNV secondary to ODD might be more sensitive than CNV secondary to age-related macular degeneration (AMD) in cases injected with a single dose of ranibizumab \[[@B13]\]. We achieved rapid response and did not observe recurrence in cases injected with 3 doses of aflibercept in the right eye and a single dose of aflibercept in the left eye and whom we followed for 12 months with OCTA.

4 different CNV patterns associated with exudative age-related macular degeneration can be detected with OCTA: Medusa pattern: central feeder vessel, circular peripheral anastomosis, thin branches, and hypointense halo; seafan pattern: eccentric feeder vessel, thin branches, and hypointense halo; indistinct network pattern: thin branches and hypointense halo; and pruned vascular tree pattern: persistence of main vascular trunks \[[@B14]\]. Pruned vascular tree pattern is considered as inactivate and usually followed up. The morphology of CNV and structural response to anti-VEGF treatment are strongly correlated. Anti-VEGF is ineffective for the vascular trunk while it is effective for especially the newly formed capillaries from preexisting vascular trunks while there is a correlation between better functional outcomes an increased vascularity of the CNV \[[@B15]\]. Spaide demonstrates reprofileration 20-50 days after the injection \[[@B16]\]. However, long-term inactivation can be ensured with fewer anti-VEGF injections in cases of CNV associated with high myopia, punctate inner choroidopathy (PIC), choroidal osteoma, optic nerve drusen like our patient, and idiopathic with lower activity than AMD \[[@B17]--[@B20]\]. The literature does not contain wide range of data which can be used to assess why stabilization can be achieved with fewer injections and make comparisons with CNV patterns of AMD with OCTA as highlighted above and assess reproliferation.

The most striking finding after injection in our case was the absence of CNV visualization in OCTA. The absence of CNV visualization in OCTA was associated with clinical and SD-OCT exudative inactivity \[[@B14]\]. In fact, inactive lesions are visualized as pruned vascular tree pattern, presence of large linear vessel with no or minimal anastomosis in OCTA. This may be due to other reasons such as the masking effect generated by a high PED, media opacities, or the presence of haemorrhages \[[@B21]\]. However, they were not observed in the follow-up of our patient. Hua and Ning demonstrated the development of atrophy in the CNV complex after 3 doses of anti-VEGF injections in PIC cases with high myopia and round dark region visualization due to no-perfusion/hypopefusion zone in the choriocapillaris \[[@B22]\]. This situation which was also observed in our case can be interpreted as decreased signal due to inactivity, but the absence of pruned vascular tree pattern may at least contribute to explaining why atrophy/shrinkage can develop in the main vascular trunk and why non-AMD CNV causes are more benign and can be stabilized longer with fewer injections.

In the literature, only Ong et al. demonstrated inactive CNV associated with ODD in 1 case with OCTA in a series of 8 paediatric patients with CNV. A 12-year-old female patient first underwent injection and photodynamic therapy in the left eye; however, OCTA revealed two large calibre vessels and a lack of fine capillaries, anastomoses, and vessel loops, which was considered as inactive sub-RPE CNV lesion \[[@B23]\]. This is the first paper to report a case with an interesting change in CNV visualization after injection and followed up for a long term for both CNV and vascular density. On the other hand, studies on OCTA for ODD mainly focus on microvascular changes. Biçer and Atilla showed that macular vascular density located in different regions decreased both at the superficial and deep capillary layer in cases with bilateral ODD, and there was a density loss in the peripapillary area especially the nasal region. They reported that ODD findings could be used to demonstrate that enlarged ODD might cause acute or chronic ischemia by compressing nerve fibers or surrounding vessel \[[@B24]\]. Aghdam et al. compared patients with ODD, NAION, and normal individuals and reported that optic nerve head vessel density was lower in the NAION group than in the other groups \[[@B25]\]. Cennamo et al. reported that flow rate measurements were correlated with ganglion cell layer thickness and OCTA examination can be an early marker to show the axonal damage in patients with ODD \[[@B26]\]. Similarly, Engelke et al. demonstrated the correlation between vascular density and RNFL and ganglion cell complex (GCC) and peripapillary capillary density loss compared to the normal group \[[@B27]\]. In our case, however, peripapillary capillary density evaluation revealed that the vascular density in the nasal quadrants was lower than those in the other quadrants, which was an interesting finding. However, changes that might be correlated in both RNFL and disc and macular vascular density measurements were not detected contrary to the abovementioned reports.

In conclusion, it is possible to evaluate vascular density, presence of associated CNV, and response to injection with OCTA in patients with optic nerve diseases such as ODD. Nonetheless, there is a need for further studies to confirm the changes in CNV visualization like in our case with OCTA that has been increasingly used.
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![On the first day. (a and d) Fundus image of the right and left eyes; elevated optic disc with blurred margin and slightly elevated yellow lesion extending from optic nerve head to the macula. (b and e) FAF image of the right and left eyes; hyperautofluorescence bodies on the surface of the optic nerve linked with the drusen and hyperautofluorescent lesion in the papillomacular region. (c and f) FFA image of the right and left eyes; hyperfluorescence and intense leakage that might be associated with CNV. (g) Orbital CT image of the right and left eyes; bright spot on papilla associated with optic disc drusen. (h) SD-OCT image of the right eye; retinal thickening, subretinal hyperreflectivity, and subfoveal fluid in the papillomacular region. (i) SD-OCT image of the left eye; retinal thickening and subretinal hyperreflectivity in the papillomacular region.](CRIOPM2020-8398054.001){#fig1}

![On the first day. (a) Unified and coloured OCTA image of the right eye; circular CNV complex with main trunk, multiple dense thin capillaries branching from the main trunk and frequent anastomoses (yellow). (b) Outer retina cross-section and en face OCTA image of the right eye. (c) Unified and coloured OCTA image of the left eye; CNV with main trunk, minimal vessel loops, and capillaries (yellow). (d) Outer retina cross-section and en face OCTA image of the left eye.](CRIOPM2020-8398054.002){#fig2}

![At 3 months. (a and b) Outer retina, choriocapillaris cross-sections, and en face OCTA image of the right eye; CNV complex including the main trunk disappearance. (c and d) Outer retina, choriocapillaris cross-sections, and en face OCTA image of the left eye; entire CNV compete of including the main trunk disappearance.](CRIOPM2020-8398054.003){#fig3}

###### 

On the first day, 3rd month, and 12th month; OCT and RNFL thickness measurements.

  Thickness (*μ*m)              Day 1   Month 3   Month 12               
  ----------------------------- ------- --------- ---------- ----- ----- -----
  *Macular*                                                               
  Fovea                         232     250       236        248   239   251
  Parafovea                     337     340       339        335   338   348
   Superior-hemi                339     342       340        338   339   350
   Inferior-hemi                335     337       337        333   336   345
   Temporal                     323     319       328        316   327   328
   Superior                     348     349       349        344   349   358
   Nasal                        335     350       335        347   332   354
   Inferior                     343     340       344        334   343   350
  Perifovea                     318     322       316        316   316   325
   Superior-hemi                322     328       317        322   315   330
   Inferior-hemi                315     316       314        310   316   320
   Temporal                     293     296       299        292   297   302
   Superior                     322     330       320        323   318   333
   Nasal                        341     349       330        342   329   346
   Inferior                     317     313       314        307   318   320
  *Retinal nerve fiber layer*                                             
  Whole                         129     126       126        125   129   134
   Superior-hemi                123     130       121        129   122   142
   Inferior-hemi                137     122       131        121   136   126
   Nasal superior               111     107       116        102   117   110
   Nasal inferior               107     97        100        91    108   98
   Inferior nasal               145     146       142        141   149   147
   Inferior temporal            195     173       202        182   211   184
   Temporal inferior            108     74        87         78    82    80
   Temporal superior            100     97        88         100   91    107
   Superior temporal            176     179       173        185   174   201
   Superior nasal               118     157       119        150   117   174

Cells are divided into two to show the results of the right and left eyes separately.

###### 

On the first day, 3rd month, and 12th month; OCTA macula and disc vascular density, FAZ, and flow measurements.

                                  Day 1   Month 3   Month 12                   
  ------------------------------- ------- --------- ---------- ------- ------- -------
  Disc-capillary density                                                        
  Radial peripapillary (%)                                                      
  Whole                           49.1    48.6      49.2       48.1    48.2    48.5
  Inside disc                     46.9    45.3      45.9       43.3    40.6    45.9
  Peripapillary                   51.7    51.0      51.1       49.5    50.7    50.4
   Superior-hemi                  50.7    50.8      51.2       49.9    50.7    50.5
   Inferior-hemi                  52.8    51.2      50.9       49      50.7    50.2
   Nasal superior                 45.8    47.8      46         47.1    46.1    46.3
   Nasal inferior                 49.1    46.6      48.4       46.6    49.6    46.3
   Inferior nasal                 53.1    50.9      52.3       45.4    51.8    48.3
   Inferior temporal              53.8    57.2      52.3       53.1    49.7    57.2
   Temporal inferior              56      51.5      51.4       52.2    51.7    51.1
   Temporal superior              57.3    55.3      57.1       56      56.7    58.2
   Superior temporal              56.1    53.2      55.9       53.3    52.4    50.9
   Superior nasal                 45.7    47.9      47.2       43.9    48.2    47.7
  Macula-capillary density                                                      
  Superficial (%)                                                               
  Whole                           52.4    53.2      54.5       54.1    53.5    51.9
  Superior-hemi                   53.5    53        54.8       53.7    53.3    51.9
  Inferior-hemi                   54.6    50.8      54.2       54.5    53.6    51.9
  Fovea                           15.2    17.1      14.6       17.7    15.7    15.3
  Parafovea                       55.3    53.6      58.2       58.1    56.8    55
   Superior-hemi                  57.1    53.5      57.8       56.6    55.9    54.1
   Inferior-hemi                  56.8    56.8      58.6       59.6    57.7    56
   Temporal                       56.2    52.8      55.5       56.5    56.1    54.1
   Superior                       58.5    55.6      58.8       57.4    57.2    53.6
   Nasal                          56.7    59.3      57.5       57.9    55.4    55.6
   Inferior                       60      55.9      61         60.5    58.4    56.8
  Perifovea                       52.8    51.8      54.3       54.5    53.3    52.9
   Superior-hemi                  53.1    53.5      54.7       54.3    52.9    53.2
   Inferior-hemi                  53.6    54.1      53.9       54.7    53.6    52.7
   Temporal                       50.3    52        51.8       52.2    50.8    52.5
   Superior                       54.2    54.7      54.7       53.9    52.4    53.1
   Nasal                          57.5    53.4      57.7       58.2    57.4    55.2
   Inferior                       53.4    52.4      52.6       53.8    52.2    50.9
  Deep (%)                                                                      
  Whole                           48.1    47.6      48.3       48.4    48      46.9
  Superior-hemi                   49.9    47.9      50.3       47.9    49.7    47.4
  Inferior-hemi                   46.4    48.5      46.4       49      46      46.4
  Fovea                           32.3    30.1      30.6       29.1    32.7    29.2
  Parafovea                       55.8    53.9      56.4       55.1    55.5    55.7
   Superior-hemi                  56.7    55.7      56.7       55.2    56.2    55.9
   Inferior-hemi                  55.6    56.2      56         54.9    54.8    55.5
   Temporal                       55.8    57.5      55         57.4    55.6    57.8
   Superior                       56.5    53.4      57.8       53.7    55.5    55.3
   Nasal                          57.9    55.2      58.3       55.9    58.1    55.8
   Inferior                       52.3    51.8      54.4       53.4    52.8    53.9
  Perifovea                       50.1    48.3      50.7       50.1    48.1    46.3
   Superior-hemi                  50.2    48.6      52.8       49.8    49      46.7
   Inferior-hemi                  48.5    47.4      48.6       50.4    47.2    45.8
   Temporal                       54.8    54.3      56.1       54.6    55.5    49.5
   Superior                       49.4    49.2      53.3       49.4    47.3    47.4
   Nasal                          43.9    43.4      46.4       46.5    44.6    42.8
   Inferior                       46.7    48.1      47.8       50      45.8    45.3
  Foveal avascular zone (mm^2^)                                                 
  Retina                          352     376       347        389     358     386
  Foveal flow                                                                   
  Outer retina                    0.558   0.732     0.346      0.846   0.602   0.665
  Choriocapillaris                2.101   2.068     2.087      2.091   2.195   2.058

Cells are divided into two to show the results of the right and left eyes separately.
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